Key result
The R133W beta-tropomyosin mutation significantly attenuated calcium-induced tropomyosin movement over the thin filament, blocking actin conformational changes and decreasing cross-bridge formation.
Why the study?
Does the R133W beta-tropomyosin mutation alter thin filament conformational changes during activation in human muscle cells?
Population
Human membrane-permeabilized muscle cells expressing a beta-tropomyosin mutation associated with a loss in…
Comparison
Addition of calcium (activation) vs Control human membrane-permeabilized muscle cells
Design
Preclinical
Authors
Loading...
Hypothesis-generating in animal models; leaves open effects on human thin filament activation and force production.
Case-Control (n=8)
No
Does the R133W beta-tropomyosin mutation alter thin filament conformational changes during activation in human muscle cells?
Absolute Event Rate: 0.128% vs 0.186%
p-value: p=<0.05
The R133W beta-tropomyosin mutation hinders calcium- and myosin-induced tropomyosin movement, blocking actin conformational changes and decreasing force production.
Ochala et al. (2010) conducted a case-control in Distal arthrogryposis type 2B (n=8). R133W beta-tropomyosin mutation vs. Healthy controls was evaluated on Second actin layer line (ALL) intensity during activation at optimal sarcomere length (2.70 μm) (p=<0.05). The R133W beta-tropomyosin mutation significantly attenuated calcium-induced tropomyosin movement over the thin filament, blocking actin conformational changes and decreasing cross-bridge formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: